Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1992 1
1995 1
1999 1
2003 1
2004 2
2005 3
2006 5
2007 11
2008 6
2009 5
2010 6
2011 8
2012 10
2013 19
2014 14
2015 16
2016 14
2017 17
2018 28
2019 39
2020 47
2021 40
2022 55
2023 61
2024 35

Text availability

Article attribute

Article type

Publication date

Search Results

400 results

Results by year

Filters applied: . Clear all
Page 1
Advances in exosome biomarkers for cervical cancer.
Ran Z, Wu S, Ma Z, Chen X, Liu J, Yang J. Ran Z, et al. Cancer Med. 2022 Dec;11(24):4966-4978. doi: 10.1002/cam4.4828. Epub 2022 May 16. Cancer Med. 2022. PMID: 35578572 Free PMC article. Review.
Risankizumab as induction therapy for Crohn's disease: results from the phase 3 ADVANCE and MOTIVATE induction trials.
D'Haens G, Panaccione R, Baert F, Bossuyt P, Colombel JF, Danese S, Dubinsky M, Feagan BG, Hisamatsu T, Lim A, Lindsay JO, Loftus EV Jr, Panés J, Peyrin-Biroulet L, Ran Z, Rubin DT, Sandborn WJ, Schreiber S, Neimark E, Song A, Kligys K, Pang Y, Pivorunas V, Berg S, Duan WR, Huang B, Kalabic J, Liao X, Robinson A, Wallace K, Ferrante M. D'Haens G, et al. Among authors: ran z. Lancet. 2022 May 28;399(10340):2015-2030. doi: 10.1016/S0140-6736(22)00467-6. Lancet. 2022. PMID: 35644154 Clinical Trial.
Risankizumab as maintenance therapy for moderately to severely active Crohn's disease: results from the multicentre, randomised, double-blind, placebo-controlled, withdrawal phase 3 FORTIFY maintenance trial.
Ferrante M, Panaccione R, Baert F, Bossuyt P, Colombel JF, Danese S, Dubinsky M, Feagan BG, Hisamatsu T, Lim A, Lindsay JO, Loftus EV Jr, Panés J, Peyrin-Biroulet L, Ran Z, Rubin DT, Sandborn WJ, Schreiber S, Neimark E, Song A, Kligys K, Pang Y, Pivorunas V, Berg S, Duan WR, Huang B, Kalabic J, Liao X, Robinson A, Wallace K, D'Haens G. Ferrante M, et al. Among authors: ran z. Lancet. 2022 May 28;399(10340):2031-2046. doi: 10.1016/S0140-6736(22)00466-4. Lancet. 2022. PMID: 35644155 Clinical Trial.
Effect of Induction Therapy With Olamkicept vs Placebo on Clinical Response in Patients With Active Ulcerative Colitis: A Randomized Clinical Trial.
Zhang S, Chen B, Wang B, Chen H, Li Y, Cao Q, Zhong J, Shieh MJ, Ran Z, Tang T, Yang M, Xu B, Wang Q, Liu Y, Ma L, Wang X, Zhang N, Zhang S, Guo W, Huang L, Schreiber S, Chen M. Zhang S, et al. Among authors: ran z. JAMA. 2023 Mar 7;329(9):725-734. doi: 10.1001/jama.2023.1084. JAMA. 2023. PMID: 36881032 Free PMC article. Clinical Trial.
Epithelial-mesenchymal transition in Crohn's disease.
Jiang H, Shen J, Ran Z. Jiang H, et al. Among authors: ran z. Mucosal Immunol. 2018 Mar;11(2):294-303. doi: 10.1038/mi.2017.107. Epub 2017 Dec 20. Mucosal Immunol. 2018. PMID: 29346350 Free article. Review.
Exosome in intestinal mucosal immunity.
Xu AT, Lu JT, Ran ZH, Zheng Q. Xu AT, et al. Among authors: ran zh. J Gastroenterol Hepatol. 2016 Oct;31(10):1694-1699. doi: 10.1111/jgh.13413. J Gastroenterol Hepatol. 2016. PMID: 27061439 Review.
Primary lymphomas in the gastrointestinal tract.
Peng JC, Zhong L, Ran ZH. Peng JC, et al. Among authors: ran zh. J Dig Dis. 2015 Apr;16(4):169-76. doi: 10.1111/1751-2980.12234. J Dig Dis. 2015. PMID: 25678011 Review.
400 results